The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described ...

The American Hospital Association is once again raising concerns about how a major drugmaker handles the government’s 340B ...

Data sovereignty key navigating 340B's future helps healthcare leaders build integrated data systems for compliance and financial resilience in 2026.

The American Hospital Association (AHA) expresses serious concerns with the recent announcement by Eli Lilly and Company (Lilly) to require 340B covered entities to submit claims data for all ...

HHS may reconsider blocked 340B rebate pilot after courts halt the program, signaling potential changes for drug discount policies in 2024.

On January 7, 2026, the First Circuit Court of Appeals denied the federal government’s emergency motion to stay a district court injunction ...

Sagebrush Health Services has filed a lawsuit against Amgen, alleging unlawful termination of discounted drug sales under the ...

The 340B Drug Pricing Program was created to help a targeted group of safety net providers care for low-income and uninsured patients. First enacted as part of the Veterans Healthcare Act of 1992, ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

Founded on pioneering research and industry leadership, ARxIUM® is committed to overcoming the most complex challenges ...

The AHA Jan. 26 urged the Health Resources and Services Administration to take immediate action to stop a new Eli Lilly and ...